Dianthus Therapeutics (DNTH) Non-Current Assets (2017 - 2025)
Dianthus Therapeutics (DNTH) posted quarterly Non-Current Assets of $121.5 million for Q4 2025, up 30.48% year-over-year from $93.1 million in Q4 2024, and down 25.75% quarter-over-quarter from $163.6 million in Q3 2025.
Dianthus Therapeutics (DNTH) Non-Current Assets (2017 - 2025) Analysis & Trends
Dianthus Therapeutics' Non-Current Assets history runs 9 years deep, the most recent figure standing at $121.5 million for Q4 2025.
- In Q4 2025, Non-Current Assets rose 30.48% year-over-year to $121.5 million; the TTM figure through Dec 2025 stood at $425.2 million (up 158.19% YoY), while the FY2025 annual figure was $121.5 million, up 30.48% from the prior year.
- Non-Current Assets for Q4 2025 stood at $121.5 million, down from $163.6 million in the prior quarter.
- The five-year high for Non-Current Assets was $163.6 million in Q3 2025, with the low at $1.0 million in Q3 2023.
- The 5-year median for Non-Current Assets is $21.1 million (2021), against an average of $40.7 million.
- The sharpest annual moves came in 2023 and 2024: Non-Current Assets plunged 96.85% in 2023, then surged 6516.35% in 2024.
- Dianthus Therapeutics' Non-Current Assets stood at $9.2 million in 2021, then sank by 88.35% to $1.1 million in 2022, then jumped by 81.43% to $2.0 million in 2023, then jumped by 4664.79% to $93.1 million in 2024, then jumped by 30.48% to $121.5 million in 2025.
- Business Quant data shows DNTH's Non-Current Assets at $121.5 million in Q4 2025, $163.6 million in Q3 2025, and $62.5 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Dianthus Therapeutics | 4.97 Bn | 4.57 Bn | - | 121.48 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 121.48 Mn |
| Sep 30, 2025 | 163.62 Mn |
| Jun 30, 2025 | 62.47 Mn |
| Mar 31, 2025 | 77.58 Mn |
| Dec 31, 2024 | 93.10 Mn |
| Sep 30, 2024 | 66.76 Mn |
| Jun 30, 2024 | 3.27 Mn |
| Mar 31, 2024 | 1.54 Mn |
| Dec 31, 2023 | 1.95 Mn |
| Sep 30, 2023 | 1.01 Mn |
| Dec 31, 2022 | 1.08 Mn |
| Sep 30, 2022 | 32.03 Mn |
| Jun 30, 2022 | 33.08 Mn |
| Mar 31, 2022 | 34.15 Mn |
| Dec 31, 2021 | 9.24 Mn |
| Sep 30, 2021 | 9.76 Mn |
| Jun 30, 2021 | 10.19 Mn |
| Mar 31, 2021 | 9.52 Mn |
| Dec 31, 2020 | 10.09 Mn |
| Sep 30, 2020 | 10.37 Mn |